{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087630","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.341737+00:00","generated_at":"2026-06-12T05:41:36.330627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec Q2 PEDMARK revenue $3.3M, up 98% QoQ; appoints Adrian Haigh as COO","bullets":["Net product sales of PEDMARK $3.3M, a 98% sequential increase from Q1 2023.","Net loss of $5.4M ($0.21/share) vs $5.1M ($0.19/share) in Q2 2022.","Cash and equivalents $15.0M; management says sufficient for at least 12 months.","Appointed Adrian Haigh as COO; he steps down from the board of directors.","Management to present at Wedbush PacGrow Healthcare Conference on August 8-9, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087630","json":"https://secwatch.observer/filing/0001104659-23-087630.json","markdown":"https://secwatch.observer/filing/0001104659-23-087630.md","text":"https://secwatch.observer/filing/0001104659-23-087630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/0001104659-23-087630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/tm2322902d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:41:36.330627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5884f32df820d1b5c5c94415269b8e69efc1e489","claim":"FENNEC PHARMACEUTICALS INC. reported second quarter ended June 30, 2023 results: revenue $3.3 million, net income $5.4 million ($0.21 per share), EPS ($0.21 per share).","evidence_excerpt":"2023 and provided a business update. “During the second quarter, we continued to make strong progress with the U.S. commercial launch of PEDMARK ® , delivering net revenue of $3.3 million, which is a 98% increase in net revenue over the first quarter of 2023. These results reflect strong growth in patient starts and new account orders,” said Rosty Raykov, chief","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/0001104659-23-087630-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.3 million"},{"label":"Net income","value":"$5.4 million ($0.21 per share)"},{"label":"EPS","value":"($0.21 per share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}